Entering text into the input field will update the search result below

Myriad Genetics Non-GAAP EPS of -$0.12 beats by $0.05, revenue of $177.8M beats by $8.38M

Feb. 28, 2023 4:38 PM ETMyriad Genetics, Inc. (MYGN) StockBy: Gaurav Batavia, SA News Editor
  • Myriad Genetics press release (NASDAQ:MYGN): Q4 Non-GAAP EPS of -$0.12 beats by $0.05.
  • Revenue of $177.8M (+10.6% Y/Y) beats by $8.38M.
  • Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek Early Gender DNA Test.
  • GeneSight, the company's pharmacogenomics test, grew revenue 36% for the full year 2022.
  • FY23 Guidance: Revenue of $720M-$750M vs consensus of $725.43M; Adj EPS loss of $(0.40)-$(0.20) vs consensus of -$0.30
  • 1Q23 Guidance: Revenue of $170M-$172M vs consensus of $725.43M; Adj EPS loss of $(0.20)-$(0.18).

Recommended For You

More Trending News

About MYGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MYGN--
Myriad Genetics, Inc.